Elena Maiolo
Research Subjects
Elena Maiolo has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Hohaus
18Ematologia, IRCCS Policlinico Universitario Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
38 shared publications - Silvia Bellesi
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
34 shared publications - Luigi Maria Larocca
Patologia Oncoematologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
30 shared publications - Adrian Andronache
Experimental Therapeutics Program, IFOM ETS - The AIRC Institute of Molecular Oncology Milan, Italy
27 shared publications - Alessandra Tucci
Hematology Division, ERN/EuroloodNet, ASST Spedali Civili di Brescia, Brescia, Italy
27 shared publications - Andrés José Maria Ferreri
Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute, Milano and Vita‐Salute San Raffaele University Milan Italy
27 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by IOS Press
- Vol. 336, 303-307
Building an RWD Oncology Data Mart for Diffuse Large B-Cell Lymphoma: From Data Integration to Clinical Insight
Introduction: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous and aggressive non-Hodgkin lymphoma, marked by wide variability in clinical presentation, biological profile, and disease course. Real World Data provide a unique opportunity to capture this complexity, offering insights into patient characteristics, disease progression, and outcomes in routine practice. Methods: This study describes the development of a DLBCL-specific Data Mart that integrates heterogeneous demographics, laboratory, histopathological, therapeutic and progression data into a standardized framework. The system supports automated identification of treatment lines and reconstruction of longitudinal patient histories, incorporating chemotherapy, radiotherapy, relapse and mortality data. An interactive dashboard displays individual disease trajectories over time. Results: The 1,235 patients Data Mart facilitates systematic analysis of therapies, patient responses, and disease progression, providing a reproducible, scalable platform for Real World Evidence generation. Conclusion: The DLBCL Data Mart demonstrates the potential of Real World Data to support research, inform clinical decision-making, and serve as a model for other oncology domains.
- 21 May 2026
- Published by IOS Press
- Vol. 336, 303-307
Open AccessBuilding an RWD Oncology Data Mart for Diffuse Large B-Cell Lymphoma: From Data Integration to Clinical Insight
Introduction: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous and aggressive non-Hodgkin lymphoma, marked by wide variability in clinical presentation, biological profile, and disease course. Real World Data provide a unique opportunity to capture this complexity, offering insights into patient characteristics, disease progression, and outcomes in routine practice. Methods: This study describes the development of a DLBCL-specific Data Mart that integrates heterogeneous demographics, laboratory, histopathological, therapeutic and progression data into a standardized framework. The system supports automated identification of treatment lines and reconstruction of longitudinal patient histories, incorporating chemotherapy, radiotherapy, relapse and mortality data. An interactive dashboard displays individual disease trajectories over time. Results: The 1,235 patients Data Mart facilitates systematic analysis of therapies, patient responses, and disease progression, providing a reproducible, scalable platform for Real World Evidence generation. Conclusion: The DLBCL Data Mart demonstrates the potential of Real World Data to support research, inform clinical decision-making, and serve as a model for other oncology domains.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
DLBCL cases included in the study.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
DLBCL cases included in the study.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Bulk and spatial gene expression data of MYC and BCL2 dual expressor DLBCL and HGBCL-DH-BCL2 (-BCL6).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Bulk and spatial gene expression data of MYC and BCL2 dual expressor DLBCL and HGBCL-DH-BCL2 (-BCL6).
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Non synonymus SNVs, IGHV gene rearrangements, AID expression status and N-glycosylation motifs in IGHV domains of HGBCL-DH-BCL2(-BCL6).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Non synonymus SNVs, IGHV gene rearrangements, AID expression status and N-glycosylation motifs in IGHV domains of HGBCL-DH-BCL2(-BCL6).